RNXT
RenovoRx, Inc.NASDAQHealthcare$0.98-4.91%ClosedMarket Cap: $35.9M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
6.07
P/S
30.41
EV/EBITDA
-2.36
DCF Value
$0.84
FCF Yield
-32.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.9%
Operating Margin
-1114.0%
Net Margin
-994.5%
ROE
-119.8%
ROA
-138.0%
ROIC
-204.0%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $238.0K | $-2.9M | $-0.08 |
| FY 2025 | $1.1M | $-11.2M | $-0.32 |
| Q3 2025 | $266.0K | $-2.9M | $-0.08 |
| Q2 2025 | $422.0K | $-2.9M | $-0.08 |
Analyst Ratings
View AllAscendiant CapitalBuy
2026-02-17Ascendiant CapitalBuy
2025-11-21Ascendiant CapitalBuy
2025-08-25Ascendiant CapitalBuy
2025-06-05HC Wainwright & Co.Buy
2025-05-19Trading Activity
Insider Trades
View AllVOLL MARKofficer: Chief Financial Officer
SellFri Mar 27
Marton Laurencedirector
BuyTue Mar 24
Bagai Shaundirector, officer: Chief Executive Officer
BuyTue Mar 24
Bagai Shaundirector, officer: Chief Executive Officer
BuyTue Mar 24
VOLL MARKofficer: Chief Financial Officer
BuyTue Mar 24
Company Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.22
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.